Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 02 April, 2002

Xenova Group PLC

Research Update

Xenova Group PLC
2 April 2002

                                Xenova Group plc

   Patient Dosing Begins in Phase IIa Dose Escalation Trial for Anti-Cocaine
                            Addiction Vaccine TA-CD

Slough, UK, 2 April, 2002 - Xenova Group plc (Nasdaq NM: XNVA; London Stock
Exchange: XEN) today announces that patient dosing has begun in a Phase IIa dose
escalation trial for Xenova's therapeutic vaccine TA-CD, which is under
development for the treatment of cocaine addiction.  The open label trial is
being conducted by Dr Thomas Kosten, Professor of Psychiatry, Yale University
School of Medicine and is designed to evaluate the safety and immunogenicity of
TA-CD using a 4 or 5 dose vaccination schedule.

This study is being funded in part by the US National Institute on Drug Abuse
(NIDA).  NIDA have also supported earlier clinical work as part of this

The results of an earlier four-dose Phase IIa dose escalation study, which were
reported in July 2001, found that TA-CD was well tolerated both systemically and
locally, and was able to generate higher and earlier antibody titres than those
seen in a Phase I trial using a three-dose vaccination schedule.  Cocaine
specific antibodies were found to persist throughout the 12 weeks of the study
and an attenuation of the usual euphoric effects of cocaine was reported amongst
five of the six patients who relapsed during the study, providing anecdotal
evidence of the benefit TA-CD may provide.

The euphoria associated with cocaine abuse is believed to be due to blockade of
dopamine uptake in the brain.  TA-CD is designed to work by generating
antibodies in the bloodstream, thus preventing cocaine from crossing from the
bloodstream into the brain.   Patients may therefore be expected to benefit from
the support offered by TA-CD during sustained relapse prevention therapy that
should continue for 6 to 18 months after stopping cocaine.

David Oxlade, Chief Executive Officer of Xenova, commented:

'TA-CD has shown considerable promise to date. With more than a million cocaine
users in the US alone, there is a real need for an effective therapy to help
habitual cocaine users to overcome their problems of drug abuse and addiction.'


UK:                                                 US:
Xenova Group plc                                    Trout Group/BMC Communications
Tel: +44 (0)1753 706600                             Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer             Press: Brad Miles (Ext 17) Lauren Tortorete (Ext 20)
Daniel Abrams, Group Finance Director               Investors: Jonathan Fassberg (Ext 16) Lee Stern (Ext 22)
Hilary Reid Evans, Corporate Communications

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates / Fiona Noblet

                                Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova currently has a broad pipeline of
eight products in clinical development.  Xenova's lead programme is a
P-glycoprotein antagonist for the treatment of multi-drug resistance in cancer,
known as tariquidar or XR9576.  Tariquidar has completed a successful series of
three Phase IIa clinical trials and is expected to enter Phase III clinical
development in the first half of 2002.  Tariquidar was partnered for the North
American market with QLT Inc in August 2001. The Group has a well-established
track record in the identification, development and partnering of innovative
products and technologies and has partnerships with other major pharmaceutical
companies including Lilly, Pfizer, Celltech and Millennium Pharmaceuticals.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialisation of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange